Veradermics Shares Surge 17% After 30–38 Hair/cm² Gains in Phase 2/3 Trial
Veradermics reported Phase 2/3 Study ’302’ topline data showing mean non-vellus hair increases of 30.3 hairs/cm² with once-daily and 37.7 hairs/cm² with twice-daily dosing versus placebo, with all primary and key secondary endpoints met across 519 participants. Patient-reported improvement rates reached 79.3% and 86.0% for once- and twice-daily dosing, respectively.
1. Trial Results and Hair Count Improvements
Veradermics enrolled 519 participants in Phase 2/3 Study ’302’ of VDPHL01, achieving all primary and key secondary endpoints with statistical significance. Once-daily dosing delivered a mean non-vellus hair increase of 30.3 hairs/cm² versus placebo, while twice-daily dosing showed 37.7 hairs/cm² gains by month 6.
2. Safety and Tolerability Observations
VDPHL01 was generally well tolerated over six months, with adverse event rates comparable to placebo and no serious treatment-related or cardiac safety issues. Discontinuation rates were lower in both dosing cohorts than placebo, supporting a favorable benefit-risk profile.
3. Market Potential and Next Steps
If approved, VDPHL01 would be the first non-hormonal oral therapy for pattern hair loss in the US, addressing an 80 million-person market. Veradermics has completed enrollment for a second Phase 3 Study ’304’, with topline results expected in H2 2026.